Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Medicine & Life Sciences

• 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 100%
• Chronic Renal Insufficiency 58%
• Albumins 55%
• Type 2 Diabetes Mellitus 48%
• Creatinine 40%
• Albuminuria 30%
• Placebos 14%
• Glomerular Filtration Rate 8%
• Sodium-Glucose Transporter 2 Inhibitors 6%
• Random Allocation 4%
• Sweden 4%
• Renal Insufficiency 3%
• Appointments and Schedules 3%
• Randomized Controlled Trials 2%
• Kidney 2%
• Therapeutics 1%